Lupin Gains FDA Tentative Nod for Apixaban Oral Suspension

Event summary

Lupin received tentative FDA approval for its Apixaban Oral Suspension 1.25mg/mL via the 505(b)(2) pathway on September 28, 2026.
The product is an oral liquid formulation of apixaban, the active ingredient in Bristol Myers Squibb's Eliquis.
Final approval will enable manufacturing at Lupin's Somerset, New Jersey facility.
Vinita Gupta, CEO of Lupin, highlighted the product's role in addressing patient needs and expanding therapeutic options.

The big picture

Lupin's tentative approval for Apixaban Oral Suspension underscores its strategy of expanding into complex generics and specialty medicines. The move aligns with broader industry trends toward patient-centric formulations, particularly for patients with difficulty swallowing tablets. The approval also reinforces Lupin's focus on leveraging U.S.-based manufacturing to strengthen its position in the cardiovascular therapy space.

What we're watching

Regulatory Timeline: The pace at which Lupin secures final FDA approval will determine market entry timing.
Market Differentiation: Whether Lupin can carve out a niche with this formulation amid Eliquis's established dominance.
Manufacturing Execution: How effectively Lupin scales production at its New Jersey facility to meet demand.